



**Trinity College Dublin**  
Coláiste na Tríonóide, Baile Átha Cliath  
The University of Dublin

# **IONIC LIQUIDS OF CIPROFLOXACIN**

A dissertation submitted for the degree of

MSc in Pharmaceutical Sciences

At School of Pharmacy and Pharmaceutical Science,

Trinity College Dublin

The University of Dublin, Ireland

by Thuong Phan Xuan

Under the supervision of Dr. Lidia Tajber

June 2018

## **Declaration and Statement of Plagiarism**

I have read and I understand the plagiarism provisions in the General Regulations of the University Calendar for the current year, found at: <http://www.tcd.ie/calendar>.

I have also completed the Online Tutorial on avoiding plagiarism 'Ready, Steady, Write', located at <http://tcd-ie.libguides.com/plagiarism/ready-steady-write>.

I declare that the content of the dissertation has not been submitted as an assignment for a degree at Trinity College Dublin or any other university and it is entirely my own work.

---

**Thuong Phan Xuan**

# Table of contents

ABSTRACT .....	i
Acknowledgements .....	ii
List of Abbreviations and Symbols .....	iii
List of Tables and Figures .....	iv
<b>1. INTRODUCTION .....</b>	<b>1</b>
<b>1.1. Ciprofloxacin – a challenging compound.....</b>	<b>1</b>
<b>1.2. Methods to improve the solubility of CIP .....</b>	<b>2</b>
<b>1.3. Ionic liquids.....</b>	<b>3</b>
<b>1.3.1. Definition and classification .....</b>	<b>3</b>
<b>1.3.2. Method of synthesis of ionic liquids.....</b>	<b>6</b>
<b>1.3.3. Factors should be taken into account for successful preparation of ILs .....</b>	<b>8</b>
<b>1.3.4. Characterization of ionic liquids .....</b>	<b>8</b>
<b>1.3.5. The potential of ILs in pharmaceuticals .....</b>	<b>9</b>
1.3.5.1. ILs as pharmaceutical salts.....	9
1.3.5.2. ILs as adjuvant components in drug delivery.....	9
1.3.5.3. ILs as dual-active APIs .....	10
1.3.5.4. ILs in controlling polymorphism.....	11
<b>1.3.6. Toxicity of counterions.....</b>	<b>12</b>
<b>2. MATERIALS AND METHODS .....</b>	<b>14</b>
<b>2.1. Materials.....</b>	<b>14</b>
<b>2.2. Methods .....</b>	<b>15</b>
<b>3. RESULTS AND DISCUSSION.....</b>	<b>17</b>
<b>3.1. Ciprofloxacin as an acid .....</b>	<b>17</b>
<b>3.1.1. Ciprofloxacin and amines (hexylamine, octylamine, dodecylamine, didecylmethylamine, trizma base).....</b>	<b>17</b>
<b>3.1.2. Ciprofloxacin and quaternary ammonium salts (didecyldimethylammonium bromide, benzalkonium hydrochloride).....</b>	<b>20</b>
<b>3.2. Ciprofloxacin as a base.....</b>	<b>22</b>
<b>3.2.1. Ciprofloxacin and monocarboxylic acids.....</b>	<b>22</b>
3.2.1.1. Ciprofloxacin and Propionic acid (C3) .....	22
3.2.1.2. Ciprofloxacin and Butyric acid (C4), Valeric acid (C5) .....	25
3.2.1.3. Ciprofloxacin and Hexanoic acid (C6), Heptanoic acid (C7), Caprylic acid (C8), Capric acid (C10).....	26

3.2.2. Ciprofloxacin and dicarboxylic acids (Malonic acid, Glutaric acid, Adipic acid, Pimelic acid)	30
4. CONCLUSION AND FUTURE WORKS .....	34
REFERENCES.....	36

## ABSTRACT

Ciprofloxacin (1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid) is a quinolone antibiotic which is commonly prescribed for treatment of urinary tract infection due to its broad spectrum against bacteria. However, Ciprofloxacin (CIP) is categorized as a group IV compound of Biopharmaceutics Classification System (BCS) with a poor solubility and permeability, which therefore reduces the bioavailability of this drug. There are limited number of commercial pharmaceuticals of CIP at present. Among them, the most common one is formulated as hydrochloride salt in tablets. This salt demonstrated a higher solubility than the pure CIP, however, it was seen to incompletely dissolve in intestinal fluid, therefore partially limit the bioavailability of this antibiotic.

Ionic liquids (ILs) have been becoming an emerging research area over the last decades. ILs are defined as low melting salts with the melting point  $< 100$  °C. The great advantage of ILs is their simple preparation with tunable physicochemical properties including solubility, permeability, stability, etc. Besides, the diversity of counterions which are utilized to generate ILs also offers a greater opportunity for ILs to be applied in pharmaceuticals.

The molecular structure of CIP contains both carboxylic group and secondary amino group. However, salt formation of CIP mainly focuses on the amino group whereas there is little literature on carboxylic group – based salt forms of CIP. Therefore, the aim of this research is trying to prepare the ILs of CIP, considering its acidic and basic aspects by using various bases and acids.

A number of cationic and anionic counterions for CIP were screened in this work. Three methods of production were tested: dry grinding, metathesis and cooling crystallization. The resulting compounds were assessed by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and Fourier transform infrared spectroscopy (FTIR). No new ionic phase was identified when CIP was co-processed with cationic counterions. In relation to monocarboxylic acids, only propionic acid resulted in a new phase, which may be classified as an IL, however this new phase was thermally unstable. A number of salts was obtained when CIP was reacted with dicarboxylic acids and these new salts were seen to have different solid state properties when subjected to dehydration.

Overall, while this project showed that CIP easily form salts with dicarboxylic acids but a limited potential to form ILs with cationic counterions and monocarboxylic acids.

## **Acknowledgements**

Firstly, I would like to express my deep gratitude to my supervisor, Dr. Lidia Tajber, for all her guidance and support during my research project. With her wide knowledge and dedication, she gave lots of useful advice for my project. Her sense of humor also made me feel relaxed when the results was not as expected. It was so lucky for me to have such a great supervisor like her.

I also want to give my thanks to my co-supervisor, Ms Klaudia Bialek for instructing me to use instruments during my lab working. She was so enthusiastic to give me a hand whenever I need in experiments as well as explaining data. I also want to thank all lectures at School of Pharmacy and Pharmaceutical Sciences for valuable knowledge they passed on me during the master's course. I would also thanks my friends in our class for their help and friendship over a year.

I would like to give my thanks to the Irish Aid Scholarship which offered me a great opportunity to study in Trinity. Besides, I had a chance to learn about Irish culture and enjoy beautiful landscape in Ireland.

Finally, I would like thank my dad and my aunt who worked so hard to give me educational opportunity. No words can express my deep gratitude for them.

## List of Abbreviations and Symbols

CIP	Ciprofloxacin
$2\theta$	2 theta (diffraction angle)
C3	Propionic acid
C4	Butyric acid
C5	Valeric acid
C6	Hexanoic acid
C7	Heptanoic acid
C8	Caprylic acid
C10	Capric acid
DDAB	Didecyldimethylammonium bromide
Bz.HCl	Benzalkonium hydrochloride
DSC	Differential Scanning Calorimetry
PXRD	Powder X-ray Diffraction
FTIR	Fourier Transform Infrared Spectroscopy
ILs	Ionic liquids
API	Active pharmaceutical ingredient
DCM	Dichloromethane
TGA	Thermal gravimetric analysis

## List of Tables and Figures

Table 1.	Some API-ILs in literature
Table 2.	Strength, weakness as well as opportunities and threats of ILs for pharmaceutical application
Table 3.	Summary of results of the current research project
Figure 1.	Chemical structure of CIP in unionized form (a) and zwitterionic form (b)
Figure 2.	The increasing number of publications in IL over two decades
Figure 3.	Some common cations and anions used in ionic liquids
Figure 4.	The evolution of ionic liquids
Figure 5.	Chemical structures of basic (a) and acid reagents (b) employed
Figures 6-10.	PXRD analysis of product obtained from reaction of Ciprofloxacin (CIP) with Hexylamine, Octylamine, Dodecylamine, Trizma base and Didecylmethylamine, respectively.
Figures 11-15	DSC thermograms of product obtained from reaction of Ciprofloxacin (CIP) with Hexylamine, Octylamine, Dodecylamine, Trizma base and Didecylmethylamine, respectively
Figure 16.	FTIR results of CIP and obtained oil product
Figure 17.	FTIR results of products obtained from reaction of CIP and Bz
Figure 18.	PXRD pattern of CIP-Bz crystals
Figure 19.	DSC thermogram of CIP-Bz crystals
Figure 20.	PXRD analysis of products obtained from experiments between CIP and C3
Figure 21.	DSC analysis of products obtained from experiments between CIP and C3
Figure 22.	FTIR results of products obtained from experiments between CIP and C3
Figures 23-24.	PXRD pattern of products obtained from experiments between CIP and C4, C5
Figures 25-26.	FTIR results of products obtained from experiments between CIP and C4, C5
Figures 27-28.	DSC analysis of products obtained from experiments between CIP and C4, C5.
Figures 29-32.	PXRD pattern of products obtained from experiments between CIP and C6, C7, C8 and C10.
Figures 33-36.	FTIR results of products obtained from experiments between CIP and C6, C7, C8 and C10.
Figures 37-40.	DSC analysis of products obtained from experiments between CIP and C6, C7, C8 and C10.
Figure 41.	FTIR of salt forms of CIP and dicarboxylic acids



Figures 42-45. PXRD pattern of salt forms of CIP and dicarboxylic acids

Figures 46-49. DSC thermogram of salt forms of CIP and dicarboxylic acids